IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C

Affiliations

¹ Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri.
² Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina.
³ Division of Infectious Diseases, Massachusetts General Hospital, Boston.
⁴ Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona.
⁵ Liver Center and Gastroenterology Division, Massachusetts General Hospital, Boston.
⁶ Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor.

Comment

William G Powderly et al. Clin Infect Dis. 2017.

. 2017 Nov 13;65(11):1773-1775.

doi: 10.1093/cid/cix620.

¹ Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri.
² Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina.
³ Division of Infectious Diseases, Massachusetts General Hospital, Boston.
⁴ Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona.
⁵ Liver Center and Gastroenterology Division, Massachusetts General Hospital, Boston.
⁶ Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor.

No abstract available

Keywords: antivirals; hepatitis C; treatment.

Comment on

Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Jakobsen JC, et al. Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD012143. doi: 10.1002/14651858.CD012143.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2017 Sep 18;9:CD012143. doi: 10.1002/14651858.CD012143.pub3. PMID: 28585310 Free PMC article. Updated.